APA (7th ed.) Citation

Hammitt, L. L., Quinn, D., Janczewska, E., Pasquel, F. J., Tytus, R., Reddy, K. R., . . . Buchwald, U. K. (2022). Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY). Open Forum Infectious Diseases, 9(3), 1. https://doi.org/10.1093/ofid/ofab605

Chicago Style (17th ed.) Citation

Hammitt, Laura L., et al. "Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)." Open Forum Infectious Diseases 9, no. 3 (2022): 1. https://doi.org/10.1093/ofid/ofab605.

MLA (9th ed.) Citation

Hammitt, Laura L., et al. "Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)." Open Forum Infectious Diseases, vol. 9, no. 3, 2022, p. 1, https://doi.org/10.1093/ofid/ofab605.